Global methylation status of LINE-1 in pediatric myelodysplastic syndrome: a predictive biomarker of prognosis?

The evolution from MDS to AML was observed in 30% (24/80) of pediatric MDS patients, but LINE-1 methylation levels did not significantly vary between pediatric patients who showed evolution to AML (median 71.0%, 66.0-73.6%) and those who did not show leukemic evolution (median 70.0%, 63.2-77.6%) (Figure 1(E)). Myelodysplastic syndrome (MDS) comprises a heterogeneous group of clonal hematopoietic stem cell diseases, characterized by ineffective hematopoiesis, dysplastic cells, peripheral blood cytopenias, and an increased risk of evolution to acute myeloid leukemia (AML). However, as this study was the first to focus on the global DNA methylation levels of LINE-1 in pediatric MDS patients, it is necessary to confirm our results in other cohorts to provide a better understanding of the role of global DNA methylation in pediatric MDS pathogenesis. RAEB/RAEB-t (advanced MDS stages); (E) patients who did not show disease evolution and patients who showed disease evolution. [Extracted from the article]

Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)